PRLD — Prelude Therapeutics Balance Sheet
0.000.00%
- $52.06m
- -$21.15m
- $7.00m
- 27
- 35
- 67
- 38
Annual balance sheet for Prelude Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 218 | 291 | 202 | 233 | 134 |
| Prepaid Expenses | |||||
| Total Current Assets | 221 | 295 | 204 | 236 | 136 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.48 | 5.64 | 6.7 | 37.7 | 35.5 |
| Other Long Term Assets | |||||
| Total Assets | 224 | 305 | 221 | 278 | 176 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.4 | 19.2 | 21.7 | 21.8 | 25.6 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 11.4 | 19.2 | 25.1 | 40.6 | 44.1 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 212 | 286 | 195 | 237 | 131 |
| Total Liabilities & Shareholders' Equity | 224 | 305 | 221 | 278 | 176 |
| Total Common Shares Outstanding |